Experimental drug aims to slow language loss in rare brain disease
NCT ID NCT07033481
First seen Apr 08, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This early-stage study tests an experimental drug called neflamapimod in 20 people with a rare form of dementia that mainly affects speech and language, known as nonfluent variant primary progressive aphasia (nfvPPA). The goal is to see if the drug is safe and whether it can help slow the worsening of language symptoms. Participants will receive either the drug or a placebo for a set period, and researchers will track side effects and any changes in language function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Ageing Research Unit, Campus for Ageing and Vitality, Biomedical Research Building
RECRUITINGNewcastle upon Tyne, NE4 5PL, United Kingdom
Contact Email: •••••@•••••
-
Columbia University
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
Hospital of the University of Pennsylvania
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Mayo Clinic
ACTIVE_NOT_RECRUITINGRochester, Minnesota, 55905, United States
-
Northwestern Memorial Hospital
ACTIVE_NOT_RECRUITINGChicago, Illinois, 60611, United States
-
The Ohio State University
ACTIVE_NOT_RECRUITINGColumbus, Ohio, 43221, United States
-
Windsor Research Unit, Fulbourn Hospital
RECRUITINGCambridge, CB21 5EF, United Kingdom
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neflamapimod
What this could lead to
If it works, this could point toward a treatment that slows language decline in people with primary progressive aphasia.
What could go wrong
This is a very early, small study with only 20 participants. It is designed mainly to check safety, not to prove effectiveness. Many drugs that look promising in early trials fail in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.